Evidence map›Paper›PMID 41572599›Full record

ArticleDiabetes, obesity & metabolism2026

CGM-derived efficacy and overall safety of once-weekly insulin efsitora alfa (efsitora) relative to day of administration in adults with type 2 diabetes.

Thomas Martens, Tadej Battelino, Simon Heller, Anuj Bhargava, Linong Ji, Sreenivasa Murthy, Rebecca J Threlkeld, Xiaoqi Li, Ada Leticia Murro, Kristen Syring and 1 more

Abstract readLetter
PubMed Full text at PMC Publisher
In one paragraph

Article in Diabetes, obesity & metabolism, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Thomas MartensInternational Diabetes Center, HealthPartners Institute, Minneapolis, Minnesota, USA.ORCID https://orcid.org/0000-0002-9858-2138
Tadej BattelinoDepartment of Endocrinology, Diabetes and Metabolism, University Children's Hospital, University Medical Center Ljubljana, Ljubljana, Slovenia.ORCID https://orcid.org/0000-0002-0273-4732
Simon HellerDivision of Clinical Medicine, School of Medicine and Public Health, University of Sheffield, Sheffield, UK.ORCID https://orcid.org/0000-0002-2425-9565
Anuj BhargavaIowa Diabetes and Endocrinology Research Center, West Des Moines, Iowa, USA.
Linong JiDepartment of Endocrinology and Metabolism, Peking University People's Hospital, Beijing, China.ORCID https://orcid.org/0000-0003-1305-1598
Sreenivasa MurthyLife Care Hospital & Research Centre, Bangalore, India.ORCID https://orcid.org/0000-0001-5571-7357
Rebecca J ThrelkeldEli Lilly and Company, Indianapolis, Indiana, USA.
Xiaoqi LiEli Lilly and Company, Indianapolis, Indiana, USA.
Ada Leticia MurroEli Lilly and Company, Indianapolis, Indiana, USA.
Kristen SyringEli Lilly and Company, Indianapolis, Indiana, USA.ORCID https://orcid.org/0000-0003-0126-9848
Vidhi PatelEli Lilly and Company, Indianapolis, Indiana, USA.

Funding

Eli Lilly and Company
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

basal insulincontinuous glucose monitoring (CGM)insulin therapytype 2 diabetes

Identifiers

PMID41572599
PMCPMC12890756

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.